Xenon Pharmaceuticals is a biotechnology company focused on developing innovative therapies for neurological disorders. Its core products include treatments for conditions such as epilepsy and pain management. The company primarily generates revenue through the development and commercialization of its drug candidates, which are in various stages of clinical trials. Xenon aims to address unmet medical needs in the healthcare sector, leveraging its proprietary drug discovery platform.
The investment profile of Xenon Pharmaceuticals is more aligned with growth investors, given its focus on developing new therapies and potential for future revenue generation. The lack of dividends and the current negative earnings per share suggest a higher risk profile, making it less suitable for conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept volatility for potential future gains.
| Datum | Vorher | Nachher | Grund |
|---|---|---|---|
| 2026-06-03 02:57 | Halten | Verkaufen | Weak fundamentals and negative momentum raise significant risk. |
| 2026-05-20 03:36 | Verkaufen | Halten | Weak fundamentals and high risk limit upside potential. |
| 2026-05-08 15:28 | — | Verkaufen | Weak fundamentals and negative momentum raise uncertainty. |
| Datum | Analyst | Action | Ziel | Preis damals |
|---|---|---|---|---|
| 2026-05-10 14:17 | Wells Fargo | Ziel erhöht | 68 → 69 | 56.44 |
| 2026-05-08 13:46 | Needham | Ziel gesenkt | 80 → 78 | 56.545 |
| 2026-03-10 08:35 | Deutsche Bank | Ziel erhöht | 56 → 90 | 60.61 |
